CytomX to receive $5M from Regeneron for cancer drug milestone
At a glance
- $REGN today+0.56%last $957.76
- Vs industry peers+1.42 pts6-peer median −0.85% · ahead
- 52-week range3.4% below high$591.52 – $991.73
- Last reported profit$1.95Bquarter to Sep 30, 2026 · 10-Q
- In the headline$5 millionAmount
- Coverage1 this week4 in 30 days · too few stories to call a pace
Nothing reported about Regeneron Pharmaceuticals across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Options price an average move of ±8.1% by Dec 18 — the at-the-money straddle, the typical size of the move; the bands are one standard deviation.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $REGN +0.56% in the latest session.
- Timing: It was published overnight, so the session change shown belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
Regeneron Pharmaceuticals ($REGN) edged up 0.56% to $957.76 in the latest session. Over the past month it is up 22.5%. That leaves it 3.4% below its 52-week high of $991.73 and 62% above its low of $591.52, close to the top of its range. Its 52-week range spans 68% from low to high, so weekly moves of several percent are normal.
What the filings say
In its latest report (10-Q, filed Oct 30, 2026), $REGN earned $1.95B over the quarter to Sep 30, 2026 on revenue of $5.12B (+19.2% QoQ). Operations brought in $3.68B of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $2.90B. It carried $1.99B of debt against $3.66B of cash on Sep 30, 2026 — net cash of $1.67B. Its most recent filings before this story: 10-Q on Oct 30, 2026, 8-K on Oct 30, 2026, 8-K on Oct 6, 2026. Figures are as filed with the SEC; the $REGN page has the full statements.
How much coverage it is getting
This is one of 4 stories on Regeneron Pharmaceuticals in Wook's last 30 days of coverage, including 1 this week. That is a normal week for it: over the month it has averaged about 1 a week. Going by their wording, 2 read bullish, 2 neutral and 0 bearish. This one reads neutral too, in line with most of them. Seeking Alpha wrote 2 of the 4 (50%), so the count reflects one outlet's output more than broad attention.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
Coming up
$REGN earnings in 72 days — on the calendar well before this story broke.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $REGN page, and they say what management has disclosed without a reporter in between. Most of the recent coverage comes from one outlet, so check whether another newsroom has confirmed the story or is only repeating it. To run the numbers yourself, ask Wook AI above about $REGN: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
